NASDAQ · HBIO

Harvard Bioscience Inc.

$5.99 -$0.01 (-0.17%) 1D Market open

Key Metrics

$27.06M
Market cap
P/E · TTM
$85.53M
Revenue · TTM
−$9.78M
Net income
EPS · TTM $-2.22
Dividend yield
Free cash flow $1.91M
Beta · 1Y 1.89
EBITDA · TTM −$8.16M
Gross margin 58.4%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 18
    From its May 6 high, the share price fell 31%.

    Peak close $7.24 on May 6; trough close $5.00 on May 18. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -31%
  • May 12
    The stock moved -20.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 12
  • Apr 10
    The stock moved -19.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 10

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$27.06M
Enterprise value$56.17M
Shares outstanding4.5M
52-wk range$0.38 – $7.50
Avg volume · 20D987.2K
Net cash −$29.11M
Book value / share$2.28
IndustryLaboratory Analytical Instruments
ExchangeNASDAQ
About Harvard Bioscience Inc.
IPO dateDec 7, 2000
Employees339

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.32
P/FCF14.17
EV/EBITDA
EV/Sales0.66
Graham №

Profitability

Gross 58.4%
Operating -11.6%
Net -11.4%
FCF 2.2%
ROE / ROIC -26.7% · -25.0%

Financial Health

Current ratio1.99
Quick ratio1.06
Debt / equity3.60
Debt / EBITDA -4.44
Net cash −$29.11M
Working capital$23.62M

Cash Flow · TTM

Operating CF $3.08M
Capex −$1.17M
Free cash flow $1.91M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-2.6
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings